Genflow Biosciences Plc Announces Result of AGM

Rhea-AI Summary

Genflow Biosciences (LSE:GENF, OTCQB:GENFF), a leader in longevity research, announced that all resolutions at the Annual General Meeting (AGM) held on June 27, 2024, were approved.

Positive

• All resolutions at the AGM were passed, indicating strong shareholder support.

Negative

• None.

LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.

Contacts Genflow Biosciences	Harbor Access
Dr Eric Leire, CEO	Jonathan Paterson, Investor Relations
+32-477-495-881	+1 475 477 9401
	Jonathan.Paterson@Harbor-access.com
Capital Plus Partners Ltd
Keith Swann, +44 0203 821 6169
Jon Critchley, +44 0203 821 6168

About Genflow

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.

Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Genflow Biosciences PLC

View the original press release on accesswire.com

FAQ

What was announced in Genflow Biosciences' latest press release?

Genflow Biosciences announced that all resolutions at the Annual General Meeting held on June 27, 2024, were passed.

When did Genflow Biosciences hold their Annual General Meeting?

Genflow Biosciences held their Annual General Meeting on June 27, 2024.

What is the stock symbol for Genflow Biosciences?

Genflow Biosciences is traded under the stock symbols LSE:GENF and OTCQB:GENFF.

What resolutions were passed at Genflow Biosciences' AGM?

The press release did not specify the resolutions, but all proposed resolutions were passed.